RecruitingPhase 1NCT06181032

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

A Single-arm Prospective Clinical Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin for the Neoadjuvant Treatment of Biliary Tract Malignancies

Sponsor

First Affiliated Hospital of Fujian Medical University

Enrollment

35 participants

Start Date

Dec 23, 2023

Study Type

INTERVENTIONAL

Conditions

Biliary Tract Malignancies

Summary

Evaluating the efficacy and safety of adebrelimab in combination with apatinib, gemcitabine and cisplatin in the neoadjuvant treatment of patients with biliary tract malignancies.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adebrelimab, a drug called Apatinib, and others for people with biliary tract malignancies. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAdebrelimab

Adebrelimab: 1200mg or 20mg/kg, iv, D1, Q3W;

DRUGApatinib

Apatinib: 250 mg, po, QD, Q3W;

DRUGGemcitabine

Gemcitabine: 1000 mg/m2, iv, 30min, D1, D8, Q3W;

DRUGCisplatin

Cisplatin: 25 mg/m2, iv, 30min, D1, D8, Q3W; Injection sequence: adebelizumab → gemcitabine → cisplatin (sequential interval of at least 30 min), 3 cycles of neoadjuvant therapy.

Locations(1)

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06181032